Anke Bio's Terlipressin Acetate API Approved for Market

Regulation
โดย 证券时报·Read original
Summary · why it matters

Anke Bio announced that its wholly-owned subsidiary, Shanghai Suhao Yiming Pharmaceutical Co., Ltd., has received the Chemical API Marketing Authorization Approval Notice for terlipressin acetate API from the National Medical Products Administration. This API is used in the production of terlipressin preparations, which are indicated for the treatment of gastrointestinal bleeding, urogenital bleeding, postoperative bleeding, and hepatorenal syndrome.

Impact on stocks 1

Others▲ · 1 stocks
Anhui Anke BioTech Group
300009
▲ PositiveRegulationrelevance

Anke Bio's subsidiary received marketing authorization for terlipressin acetate API from NMPA.

Off-coverage companies 1

上海苏豪逸明制药有限公司Private▲ Positive
Regulationrelevance

Shanghai Suhao Yiming Pharmaceutical received the API marketing authorization approval.

© 2026 MarketDXNews